GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Precipio Inc (FRA:TGK) » Definitions » Loans Receivable

Precipio (FRA:TGK) Loans Receivable : €0.00 Mil (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Precipio Loans Receivable?

Precipio's Loans Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.


Precipio Loans Receivable Historical Data

The historical data trend for Precipio's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precipio Loans Receivable Chart

Precipio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Precipio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Precipio Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Precipio Loans Receivable Related Terms

Thank you for viewing the detailed overview of Precipio's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Precipio (FRA:TGK) Business Description

Traded in Other Exchanges
Address
4 Science Park, New Haven, CT, USA, 06511
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings.

Precipio (FRA:TGK) Headlines

No Headlines